[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"beta-blocker\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:beta-blocker":31},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,4,0,[8,52,84,112],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":33,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":40,"lastUpdatePostDateStruct":41,"startDateStruct":44,"completionDateStruct":46,"leadSponsor":48,"locationsCount":51},"100605891","phase-4-landiolol-to-avoid-tachycardia-in-patients-at-risk-for-cardiovascular-events-undergoing-major-non-cardiac-surgery-100605891",false,"NCT07168421","LANdiolol to Avoid TAchycardia in Patients at Risk for Cardiovascular Events Undergoing Major Non-cardiac Surgery","LANdiolol to Avoid TAchycardia in Patients at Risk for Cardiovascular Events Undergoing Major Non-cardiac Surgery: a Feasibility Trial","LANTA-P","Inclusion Criteria:\n\n* Patients undergoing elective non-cardiac surgery defined as intermediate or high-risk by the 2022 european society of cardiology (ESC) guidelines\n* surgery performed under general anesthesia;\n* expected length of hospital stay ≥ 24 hours;\n* age ≥ 45 years;\n* at least two of the following risk factors:\n\n  * age ≥ 75 years\n  * arterial hypertension;\n  * ischemic heart disease (history of myocardial infarction or positive exercise test, current complaint of chest pain considered to be secondary to myocardial ischemia, use of nitrates, pathological Q waves, prior coronary revascularization);\n  * history of congestive heart failure;\n  * history of cerebrovascular disease;\n  * peripheral artery disease;\n  * diabetes mellitus;\n  * GFR ≤ 59 ml\u002Fmin pro 1.73 m2;\n  * pre-operative NTproBNP \\> 200 pg\u002Fml;\n* excessive sympathetic outflow as proven by exercise testing:\n\n  * impaired heart rate recovery (≤ 12 bpm within 1 minute after cessation of exercise); OR\n  * exaggerated heart rate response (≥ 12 bpm after 3 minutes of unloaded pedalling);\n\nExclusion Criteria:\n\n* unable to consent or follow study procedures;\n* absolute contraindications for exercise testing;\n* pregnancy or intention to become pregnant;\n* active cardiac conditions (such as unstable coronary syndromes, decompensated heart failure, significant arrhythmias, severe valvular disease);\n* urgent \u002F emergency surgery;\n* already on β-blocker (within the last 30 days prior to recruitment);\n* contraindication for β-blocker therapy (bradycardia (HR \\\u003C 55 bpm), hypotension (systolic blood pressure \\\u003C 100 mmHg), severe peripheral vascular disease, severe asthma, allergy, higher-degree atrioventricular block);\n* severe preoperative anaemia (haemoglobin \\\u003C 100 g\u002FL) unless there is a plan set up and followed for correction prior to surgery;\n* planned intermediate care or intensive care admission;\n* prior enrolment in this trial.","ALL","45 Years",{"count":20,"type":21},114,"ESTIMATED","INTERVENTIONAL",[24],"PHASE4","Limiting perioperative tachycardia (aiming for a heart rate \\\u003C90 beats per minute throughout the perioperative period) using the ultra-short acting beta-blocker landiolol in patients with cardiovascular risk factors undergoing major surgery might lower the incidence of perioperative myocardial injury. Feasibility of the intervention needs to be proven prior to conduction of a larger trial.",[27,28,29,30,31,32],"Perioperative Myocardial Injury","Autonomic Dysfunction","Cardiovascular (CV) Risk","Major Surgery","Beta Blocker","Myocardial Injury After Non-cardiac Surgery",[34,35,36,37,38],"perioperative myocardial injury","major surgery","beta blocker","myocardial injury after non-cardiac surgery","autonomic dysfunction","RECRUITING","2026-05-04",{"date":42,"type":43},"2026-05-05","ACTUAL",{"date":45,"type":43},"2026-04-24",{"date":47,"type":21},"2028-03-01",{"name":49,"class":50},"Insel Gruppe AG, University Hospital Bern","OTHER",1,{"id":53,"slug":54,"hasResults":11,"nctId":55,"briefTitle":56,"officialTitle":56,"acronym":4,"eligibilityCriteria":57,"healthyVolunteers":11,"sex":17,"minAge":58,"maxAge":59,"enrollmentInfo":60,"targetDuration":4,"studyType":22,"phases":62,"briefSummary":64,"conditions":65,"keywords":69,"overallStatus":75,"whyStopped":4,"lastUpdateSubmitDate":76,"lastUpdatePostDateStruct":77,"startDateStruct":78,"completionDateStruct":80,"leadSponsor":82,"locationsCount":4},"100635224","phase-2-neoadjuvant-iparomlimabtuvonralimab-plus-capeox-versus-iparomlimabtuvonralimab-plus-capeox-and-propranolol-for-locally-advanced-pmmr-colon-cancer-a-prospective-single-center-multi-cohort-study-100635224","NCT07549906","Neoadjuvant Iparomlimab\u002FTuvonralimab Plus CAPEOX Versus Iparomlimab\u002FTuvonralimab Plus CAPEOX and Propranolol for Locally Advanced pMMR Colon Cancer: A Prospective, Single-Center, Multi-Cohort Study","Inclusion Criteria\n\nParticipants must meet all of the following:\n\n1. Diagnosis \u002F Stage: Histologically confirmed and radiologically assessed colon adenocarcinoma that is T4, or T3 with lymph node metastasis, with tumor location ≥10 cm from the anal verge, and clinical TNM staging per AJCC\u002FUICC 8th edition.\n2. Measurable disease: At least one measurable lesion per RECIST v1.1 (non-lymph node lesion long axis ≥10 mm on CT; lymph node lesion short axis ≥15 mm on CT).\n3. pMMR\u002FMSS confirmation: pMMR by IHC on colonoscopy biopsy (MMR proteins by immunohistochemistry), or MSS\u002FMSS-L by PCR or NGS.\n4. Treatment-naïve for current colon cancer: No prior anti-tumor treatment for colon cancer. (If Lynch syndrome, no anti-tumor treatment for the current diagnosis.)\n5. Age: 18 to 75 years, any sex.\n6. Performance status \u002F organ function: ECOG 0-1 with adequate organ and bone marrow function.\n7. Informed consent: Written informed consent signed before enrollment.\n8. Life expectancy: Expected survival \\>12 weeks.\n9. Hematology and chemistry (without blood products or growth factors within 14 days):\n\n   * Hemoglobin ≥60 g\u002FL\n   * ANC ≥1.5 × 10⁹\u002FL\n   * Platelets ≥75 × 10⁹\u002FL\n   * Serum creatinine ≤1.5 × ULN or creatinine clearance ≥50 mL\u002Fmin (Cockcroft-Gault)\n   * Total bilirubin ≤1.5 × ULN\n   * AST or ALT ≤2.5 × ULN (if abnormal due to liver metastasis, ≤5 × ULN)\n   * Urine protein \\\u003C2+; if ≥2+, 24-hour urine protein ≤1 g\n10. Coagulation \u002F bleeding-thrombosis status: No active bleeding and no thrombotic disease; patients may be eligible if thrombosis is treated and stable for ≥3 months. Must meet:\n\n    * INR ≤1.5 × ULN\n    * APTT ≤1.5 × ULN\n    * PT ≤1.5 × ULN\n11. Thyroid function within normal range:\n\n    * Free T4 12-22 pmol\u002FL\n    * Free T3 2.8-7.1 pmol\u002FL\n    * TSH 0.27-4.2 mIU\u002FL\n12. Blood pressure requirement (screening): Average seated BP 100-150 \u002F 60-90 mmHg, and 24-hour ambulatory BP below the threshold for Grade I hypertension.\n13. Contraception \u002F pregnancy test (for women of childbearing potential): Must use medically approved contraception during treatment and for 3 months after; pregnancy test (serum or urine HCG negative within 7 days prior to enrollment); not breastfeeding.\n14. Compliance: Willing and able to comply with study procedures and safety\u002Fsurvival follow-up.\n\nExclusion Criteria\n\nParticipants meeting any of the following are excluded:\n\n1. History of allergic disease, severe drug allergy, known allergy to macromolecular protein products, or allergy to Iparomlimab\u002FTuvonralimab (protocol wording originally referenced the Chinese drug name).\n2. Cardiopulmonary insufficiency or hepatic\u002Frenal insufficiency such that CAPEOX cannot be tolerated; known allergy to oxaliplatin or capecitabine.\n3. Presence of distant metastasis.\n4. Any of the following complications:\n\n   * Major GI bleeding, perforation, or GI obstruction (including paralytic ileus)\n   * Symptomatic heart disease (including unstable angina, myocardial infarction, heart failure)\n   * Uncontrolled diabetes, hypertension, or hypotension\n   * Uncontrolled diarrhea that interferes with daily activities despite adequate treatment\n   * Use of immunosuppressants or systemic\u002Fabsorbable local steroids for immunosuppression (\\>10 mg\u002Fday prednisone equivalent) and still using within 2 weeks before enrollment\n5. Poorly controlled cardiac symptoms or clinically significant heart disease, including:\n\n   * NYHA class \\>II heart failure\n   * Unstable angina\n   * Myocardial infarction within 1 year\n   * Clinically significant supraventricular or ventricular arrhythmia requiring treatment\u002Fintervention\n6. Prior or current thyroid dysfunction that cannot be maintained within normal range despite medication.\n7. Use of traditional Chinese immune modulators within 2 weeks before treatment, or receipt of systemic anti-tumor therapy (chemotherapy, immunotherapy, biologic therapy, etc.) or TCM anti-tumor therapy within 4 weeks before treatment.\n8. Active infection, or unexplained fever \\>38.5°C during screening or before first dose (tumor-related fever may be allowed per investigator judgment).\n9. History or current objective evidence of pulmonary fibrosis, interstitial pneumonia, pneumoconiosis, radiation pneumonitis, drug-related pneumonitis, known active pulmonary tuberculosis, severely impaired lung function, etc.\n10. Congenital or acquired immunodeficiency, e.g., HIV infection (HIV 1\u002F2 antibody positive).\n11. Acute or chronic active HBV: HBsAg(+) or HBcAb(+) requires HBV DNA testing. Eligible only if HBV DNA \\\u003C2×10³ copies\u002FmL or \\\u003C200 IU\u002FmL or below LLOD; HBsAg(+) must receive anti-HBV therapy during study treatment; HBcAb(+)\u002FHBsAg(-)\u002Fanti-HBs(-) with negative viral load does not require prophylaxis but requires close monitoring.\n12. Acute or chronic active HCV: HCV antibody positive and HCV RNA above LLOD.\n13. Receipt of a live vaccine within 4 weeks prior to study drug or anticipated need for live vaccination during the study.\n14. Known history of psychoactive substance abuse, alcoholism, or drug abuse.\n15. Pregnant or breastfeeding women, or men\u002Fwomen unwilling to use contraception.\n16. History of allergy to β-blockers.\n17. Asthma, COPD, or other respiratory disease requiring bronchodilator therapy.\n18. Definite history of hypertension (without antihypertensives: non-same-day 3 measurements with SBP ≥140 mmHg and\u002For DBP ≥100 mmHg, or currently receiving antihypertensive therapy).\n19. Clear history of hypotension; baseline SBP \\\u003C90 mmHg or DBP \\\u003C60 mmHg.\n20. Any other condition judged by the investigator to warrant exclusion (e.g., factors that may force early termination of study participation).","18 Years","75 Years",{"count":61,"type":21},45,[63],"PHASE2","The goal of this prospective, single-center, multi-cohort clinical trial is to evaluate the efficacy and safety of neoadjuvant Iparomlimab\u002FTuvonralimab combined with CAPEOX, with or without propranolol, in patients with locally advanced pMMR (MSS) colon cancer. The main questions it aims to answer are:\n\n* What is the major pathological response (MPR) rate after neoadjuvant treatment and curative surgery (e.g., ≤10% viable tumor cells in the resected primary tumor)?\n* What are the key secondary outcomes (e.g., R0 resection rate, tumor regression grade, objective response rate, disease-free survival) and the safety\u002Ftolerability profile of these neoadjuvant regimens? If there is a comparison group: Researchers will compare Cohort A (Iparomlimab\u002FTuvonralimab + CAPEOX) versus Cohort B (Iparomlimab\u002FTuvonralimab + CAPEOX + propranolol) to see whether adding propranolol improves pathological and clinical responses while maintaining acceptable safety.\n\nParticipants will:\n\n* Receive neoadjuvant Iparomlimab\u002FTuvonralimab + CAPEOX for a protocol-defined number of cycles, with or without propranolol depending on cohort assignment.\n* Undergo curative-intent surgical resection after completing neoadjuvant therapy.\n* Be followed for postoperative treatment, adverse events, and longer-term outcomes (e.g., recurrence and survival), and may contribute tumor\u002Fblood samples for exploratory biomarker analyses related to treatment response.",[66,67,31,68],"Colon Cancer (Stage II &Amp; III)","Immunotherapy","Neoadjuvant Chemoimmunotherapy",[70,71,72,73,74],"Colon Cancer","Neoadjuvant chemoimmunotherapy","Iparomlimab\u002FTuvonralimab","propranolol","CAPEOX","NOT_YET_RECRUITING","2026-04-17",{"date":45,"type":43},{"date":79,"type":21},"2026-04-20",{"date":81,"type":21},"2026-12-31",{"name":83,"class":50},"Sun Yat-sen University",{"id":85,"slug":86,"hasResults":11,"nctId":87,"briefTitle":88,"officialTitle":89,"acronym":4,"eligibilityCriteria":90,"healthyVolunteers":11,"sex":17,"minAge":91,"maxAge":4,"enrollmentInfo":92,"targetDuration":4,"studyType":22,"phases":94,"briefSummary":96,"conditions":97,"keywords":101,"overallStatus":75,"whyStopped":4,"lastUpdateSubmitDate":104,"lastUpdatePostDateStruct":105,"startDateStruct":107,"completionDateStruct":108,"leadSponsor":110,"locationsCount":4},"100630567","n-of-1-trial-to-promote-beta-blocker-titration-in-heart-failure-100630567","NCT07489352","N-of-1 Trial to Promote Beta-Blocker Titration in Heart Failure","N-of-1 Trials to Promote Patient-Centered Beta-Blocker Titration in Heart Failure With Reduced Ejection Fraction","Inclusion Criteria:\n\n* Adults aged ≥60 years\n* Diagnosed with HFrEF (LVEF \\\u003C40%)\n* Taking below 50% of guideline-based target β-blocker dose (guideline-based target doses: metoprolol 200mg daily; carvedilol 25mg BID; bisoprolol 10mg daily)\n\nExclusion Criteria:\n\n* Contraindication to beta-blocker including allergy\n* Treating physician disapproval of enrollment\n* Clinical instability","60 Years",{"count":93,"type":21},50,[95],"NA","In this study we seek to understand whether N-of-1 trials using a crossover withdrawal\u002Freversal design with as many 2-week periods can be used to identify the highest tolerated beta-blocker dose for patients with Heart Failure with Reduced Ejection Fraction (HFrEF). To achieve this objective we will conduct a 2-arm randomized controlled trial of 50 participants, comparing intervention(N-of-1 trials) to enhanced usual care.\n\nFor participants randomized to the intervention, we will use collect data via validated patient-reported outcomes and then display this data on a visualization tool. This tool was iteratively developed for N-of-1 trials with patient input - a comparison of how the patient felt on different beta-blockers. If well-tolerated and the participant agrees to continue with dose escalation based on review of their data, the participant will take a higher dose for the next 2-week period; and the study team will again collect data on how they feel during this time. This approach of sharing end-of-period data with participants and subsequently escalating the dose (based on the participant's decision) for another 2-week period will continue until the guideline-directed target dose is reached or until the participant feels that their symptoms are limiting dose escalation. The N-of-1 intervention is purposefully structured to allow the participant to participate in as many periods (and as many dose combinations) as they wish until they are confident that they have reached their highest tolerated dose. This adaptive design for N-of-1 trials is intended to be patient-centered and patient-driven.\n\nWe will also conduct brief semi-structured interviews with intervention participants.\n\nParticipants randomized to enhanced usual care will not have access to patient-reported outcomes or the data visualization tool. Since attention can affect outcomes, we will \"enhance usual care\" by conducting phone calls at the same frequency as the intervention group.",[98,99,100],"Heart Failure","Beta-blocker","Older Adults",[102,103],"Guideline-directed medical therapy","N-of-1 trials","2026-03-18",{"date":106,"type":43},"2026-03-24",{"date":42,"type":21},{"date":109,"type":21},"2027-03-05",{"name":111,"class":50},"Brigham and Women's Hospital",{"id":113,"slug":114,"hasResults":11,"nctId":115,"briefTitle":116,"officialTitle":117,"acronym":118,"eligibilityCriteria":119,"healthyVolunteers":11,"sex":17,"minAge":58,"maxAge":4,"enrollmentInfo":120,"targetDuration":4,"studyType":22,"phases":122,"briefSummary":124,"conditions":125,"keywords":129,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":132,"lastUpdatePostDateStruct":133,"startDateStruct":135,"completionDateStruct":137,"leadSponsor":139,"locationsCount":51},"100419981","phase-3-comparison-of-landiolol-versus-standard-of-care-for-prevention-of-mortality-in-patients-hospitalized-for-a-septic-shock-with-hypercontractility-100419981","NCT04748796","Comparison of Landiolol Versus Standard of Care for Prevention of Mortality in Patients Hospitalized for a Septic Shock With Hypercontractility","Comparison of Landiolol Versus Standard of Care for Prevention of Mortality in Patients Hospitalized for a Septic Shock With Hypercontractility: an Open Label Prospective Randomized Study","HyperBetashock","Inclusion Criteria:\n\n* Age ≥ 18 years old\n* Patient admitted for a septic shock (according to the SEPSIS3 definition: sepsis with persisting hypotension (MAP\\\u003C65mmHg or SAP \\\u003C90mmHg) requiring vasopressors to maintain MAP\\>65mmHg and having a serum lactate level \\>2 mmol\u002FL\n* Patient who received at least 30ml\u002Fkg of fluid and absence of fluid responsiveness\n* Left ventricular ejection fraction \\>65% (visual or Simpson method using echocardiography)\n* Tachycardia \\>100 bpm in sinus rhythm with a MAP 65mmHg for more than 1 hour\n* Patient receiving invasive mechanical ventilation\n* Patients adapted to the ventilator under sedation and analgesia\n* Written informed consent\n* Patient covered by French national health insurance\n\nExclusion Criteria:\n\n* Patients with inclusion criteria already present for more than 36 hours\n* Patient treated with Dobutamine, adrenaline or isoprenaline\n* Patient currently treated with beta blockers (previous home betablocker treatment is not an exclusion criteria)\n* Supra ventricular (atrial fibrillation or flutter) or ventricular arrhythmias\n* Patients with any form of cardiac pacing\n* Sick sinus syndrome\n* Severe atrioventricular (AV) nodal conductance disorders (without pacemaker): 2nd or 3rd degree AV block\n* Known pulmonary hypertension\n* ScVO2 \\\u003C70%\n* Moribund\n* Cardiac arrest\n* Non-treated phaeochromocytoma\n* Acute asthmatic attack\n* Pregnant or breastfeeding woman\n* Patient deprived of liberty by administrative or judicial decision or placed under judicial protection (guardianship or supervision),\n* Age \\\u003C18 years\n* Hypersensitivity to the active substance or to any of the excipients\n* Severe bradycardia (less than 50 beats per minute)\n* Cardiogenic shock\n* Severe hypotension\n* Decompensated heart failure when considered not related to the arrhythmia\n* Severe, uncorrectable metabolic acidosis\n* Presence of significant bleeding, or\n* Acute respiratory distress defined by increased oxygen dependency, polypnea \\> 30 \u002Fmin, signs of struggle (pulling, thoraco-abdominal sway) if the patient is not intubated and ventilated.",{"count":121,"type":21},360,[123],"PHASE3","Several data emphasize the relation between tachycardia (\\>90\u002Fmin) and high mortality during septic shock. The investigators previously demonstrated the high mortality associated with hypercontractility, tachycardia and the presence of a left ventricular obstruction. A severe hypovolemia, a hyper adrenergic stimulation or a severe vasoplegia can all explain this relation between tachycardia, hypercontractility and the mortality during septic shock.\n\nLandiolol is another short-term acting beta-blocker with a half-life of 4 minutes without any beta 2 activity or membrane stabilizing effect. The landiolol has been used in critically ill patients to control supraventricular tachycardia but not in this context of tachycardia and septic shock. The investigators hypothesize that landiolol by reducing the heart rate may improve the survival of patients treated for a septic shock and presenting with an hypercontractility state.",[126,127,128,99],"Septic Shock","Tachycardia","Mortality During Septic Shock",[126,127,130,131],"mortality during septic shock","beta-blocker","2025-08-19",{"date":134,"type":43},"2025-08-24",{"date":136,"type":43},"2021-02-01",{"date":138,"type":21},"2027-09",{"name":140,"class":50},"Centre Hospitalier Universitaire, Amiens"]